Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a Double Blind, Randomized, Parallel Arm, Placebo-controlled Trial to Investigate the Effects of Two Dose Levels of CIT-013 on Disease Activity in Patients With Hidradenitis Suppurativa

Next Previous
Trial Profile

A Phase 2a Double Blind, Randomized, Parallel Arm, Placebo-controlled Trial to Investigate the Effects of Two Dose Levels of CIT-013 on Disease Activity in Patients With Hidradenitis Suppurativa

Status: Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CIT 013 (Primary)
  • Indications Hidradenitis suppurativa
  • Focus Proof of concept; Therapeutic Use
  • Acronyms Citylights
  • Sponsors Citryll

Most Recent Events

  • 28 May 2025 Status changed from planning to not yet recruiting.
  • 16 Dec 2024 According to a Citryll media release, company will initiate this trial in 2025.
  • 13 Feb 2024 According to a Citryll media release, company anticipates the initiation of this trial later this year.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top